MapQuant Dx™ genomic profiling solution is an integrated series of products & services for molecular diagnostic testing.
With MapQuant Dx™ solution one can accurately quantify, the expression of all known genes in tumor specimens and get a comprehensive view of tumor biology. Proprietary computation of the tumor expression profile allows the identification of key characteristics of the tumor and subsequently guides therapeutic decisions.
The whole platform was tailored so that pathologists, laboratories and oncologists can integrate it in their routine in a snap. The diagnostic value of MapQuant Dx™ tests is validated by comprehensive clinical trials.
Today, the MapQuant Dx™ solution allows to deliver the MapQuant Dx™ Genomic Grade test, which includes:
the MapQuant Dx™ Path Kit, CE-marked, ensuring easy sampling, RNA-preservation and shipping at ambient temperature;
the ISO 17025 Map
Quant Dx™ Lab Services performed by
DNAVision SA (Gosselies, Belgium) using
Affymetrix GeneChip® Systems 3000Dx2 (GCS3000Dx2) platform ensuring highly reproducible sample processing;
the MapQuant Dx™ CE-compliant data analysis, ensuring highly reliable quality controls, data processing and genomic indexes computation.
The MapQuant Dx™ solution is developed under the innovation support program of the French Health Products Safety Agency (AFSSaPS).
